Last reviewed · How we verify

Reinier de Graaf Groep — Portfolio Competitive Intelligence Brief

Reinier de Graaf Groep pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
spinal administration of articaine spinal administration of articaine phase 3 Local anesthetic (amide) Voltage-gated sodium channels Anesthesia
spinal administration of bupivacaine spinal administration of bupivacaine phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Beijing Tiantan Hospital · 1 shared drug class
  3. Bozyaka Training and Research Hospital · 1 shared drug class
  4. Centre Hospitalier Departemental Vendee · 1 shared drug class
  5. Centre Hospitalier Universitaire de Nīmes · 1 shared drug class
  6. Chiang Mai University · 1 shared drug class
  7. China Medical University, China · 1 shared drug class
  8. ASST Gaetano Pini-CTO · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Reinier de Graaf Groep:

Cite this brief

Drug Landscape (2026). Reinier de Graaf Groep — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/reinier-de-graaf-groep. Accessed 2026-05-17.

Related